• Number of patients treated increased by around 12 percent to more than 2.5 million
• Revenue grew by approx. 9 percent to €2.86 billion
• Financial results for 2012 strongly impacted by one-time effects
• EBITDA deteriorated by around 14 percent to €292 million
• Net consolidated profit fell by approx. 43 percent to €92 million

Patients of RHÖN-KLINIKUM AG appeared to be largely unfazed by the occasional periods of turbulence that characterized the 2012 financial year: at more than 2.5 million, more people were treated in the Group’s facilities than ever before. This strong increase in patient numbers enabled RHÖN-KLINIKUM AG to set a new revenue record of €2.86 billion.

The commitment of our management resources to non-operational matters following the take-over attempt by Fresenius had a negative impact on our operations last year. This factor combined with one-off costs, such as substantial consulting costs and personnel changes on our management board, caused a decline in net consolidated profit by around 43 % to €92 million. EBITDA amounted to around €292 million in 2012 and was therefore roughly 14 % lower than the adjusted figure for the previous year. The Wiesbaden-based hospital, Dr. Horst Schmidt Kliniken (HSK), was consolidated for the first time on May 1, 2012.

“These are respectable figures in view of the extremely difficult circumstances and conditions in the 2012 financial year. But they certainly do not mean that we can rest on our laurels, and indeed we have no intention of doing so,” said Dr. Dr. Martin Siebert, Chairman of the Board of Management at RHÖN-KLINIKUM AG. CFO Jens-Peter Neumann added: “We are currently working very hard to introduce more efficient internal controlling and management tools at all locations. By increasing transparency, we will be able to control operations more precisely and create new potential to improve the current unsatisfactory earnings situation.”

Outlook

In 2013, RHÖN-KLINIKUM AG expects to exceed the €3 billion revenue threshold for the first time (€3.03 billion with a fluctuation range of 2.5 %). This target is accompanied by an EBITDA forecast of €325 million and a net consolidated profit forecast of €110 million, each with a fluctuation range of +/-5 %.

“Some of the challenges we face in 2013 are typical of the industry, while others are of our own making. It will be the shared responsibility of the management board to quickly improve the company’s position. Several necessary measures have already been rigorously implemented during the first few months of my term in office, and I am therefore cautiously optimistic that we will be able to demonstrate a more positive development within the foreseeable future, particularly with regard to the profit situation,” concluded Dr. Dr. Martin Siebert.